Gujarat Themis Biosyn balance sheet

As of Mar 2026

Total assets: ₹503cr+67.1% on Mar 2025
Shareholders' equity: ₹288cr+15.9% on Mar 2025
Total debt: ₹160cr+434.8% on Mar 2025
Cash and investments: ₹3.1cr−73.3% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025

Non-current assets
	287	40.6
	121	184
	0.1	0.0
	0.0	0.2
	2.8	0.0
	0.8	0.8
	0.9	1.6
	4.5	2.4
	2.0	21.8
	415	249
Current assets
	15.4	5.0
	60.9	31.2
	3.1	11.7
	3.0	0.9
	0.0	0.0
	0.3	1.0
	67.3	44.8
	6.0	2.1
	88.8	52.0
	503	301
Equity
	10.9	10.9
	277	237
	288	248
	288	248
Liabilities
	128	29.6
	8.4	—
	137	29.6
	0.0	0.8
	0.0	2.0
	137	32.4
	31.8	0.3
	36.7	14.6
	7.2	4.9
	75.6	19.8
	0.3	0.3
	0.1	0.0
	3.1	0.5
	79.2	20.6
	216	52.9
	503	301
Trade payables — MSME split
	0.4	0.6
	36.3	14.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

GUJTHEM₹355.55

Gujarat Themis Biosyn Limited

· Pharma & Health

₹ CrorePeersRPGLIFE GUFICBIO ORCHPHARMA UNICHEMLAB FDC IOLCP MOREPENLAB INNOVACAPMcap ₹3,874 Cr

View

In ₹ Crore except Per Share As of	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	40.6	286.9	286.9
+ Capital Work-in-Progress	184.4	121.1	121.1
+ Other Intangibles	0.0	0.1	0.1
+ Intangibles under Development	0.2	0.0	0.0
+ Non-current Investments	0.0	2.8	2.8
+ Long-term Loans	0.8	0.8	0.8
+ Other Non-current Financial Assets	1.6	0.9	0.9
Non-current Financial Assets	2.4	4.5	4.5
+ Other Non-current Assets	21.8	2.0	2.0
Total Non-current Assets	249.3	414.6	414.6
Current Assets
+ Inventories	5.0	15.4	15.4
+ Trade Receivables	31.2	60.9	60.9
+ Cash & Cash Equivalents	11.7	3.1	3.1
+ Other Bank Balances	0.9	3.0	3.0
+ Short-term Loans	0.0	0.0	0.0
+ Other Current Financial Assets	1.0	0.3	0.3
Current Financial Assets	44.8	67.3	67.3
+ Other Current Assets	2.1	6.0	6.0
Total Current Assets	52.0	88.8	88.8
Total Assets	301.3	503.4	503.4
Equity
+ Equity Share Capital	10.9	10.9	10.9
+ Other Equity / Reserves	237.5	276.9	276.9
Equity — Owners of Parent	248.4	287.8	287.8
Total Equity	248.4	287.8	287.8
Liabilities
+ Borrowings — Non-current	29.6	128.1	128.1
+ Other Non-current Financial Liab	—	8.4	8.4
Non-current Financial Liabilities	29.6	136.5	136.5
+ Provisions — Non-current	0.8	0.0	0.0
+ Deferred Tax Liabilities	2.0	0.0	0.0
Non-current Liabilities	32.4	136.5	136.5
+ Borrowings — Current	0.3	31.8	31.8
+ Trade Payables	14.6	36.7	36.7
+ Other Current Financial Liab	4.9	7.2	7.2
Current Financial Liabilities	19.8	75.6	75.6
+ Provisions — Current	0.3	0.3	0.3
+ Current Tax Liabilities	0.0	0.1	0.1
+ Other Current Liabilities	0.5	3.1	3.1
Current Liabilities	20.6	79.2	79.2
Total Liabilities	52.9	215.7	215.7
Total Equity & Liabilities	301.3	503.4	503.4
Trade Payables — MSME split
+ Dues to Micro & Small — Current	0.6	0.4	0.4
+ Dues to Other Creditors — Current	14.1	36.3	36.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.